留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

SerpinB9与肿瘤关系及其在皮肤肿瘤领域的研究进展

张姗 刘兆睿 刘洁

张姗, 刘兆睿, 刘洁. SerpinB9与肿瘤关系及其在皮肤肿瘤领域的研究进展[J]. 协和医学杂志, 2022, 13(5): 852-857. doi: 10.12290/xhyxzz.2021-0805
引用本文: 张姗, 刘兆睿, 刘洁. SerpinB9与肿瘤关系及其在皮肤肿瘤领域的研究进展[J]. 协和医学杂志, 2022, 13(5): 852-857. doi: 10.12290/xhyxzz.2021-0805
ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. doi: 10.12290/xhyxzz.2021-0805
Citation: ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. doi: 10.12290/xhyxzz.2021-0805

SerpinB9与肿瘤关系及其在皮肤肿瘤领域的研究进展

doi: 10.12290/xhyxzz.2021-0805
基金项目: 

国家自然科学基金 82173449

中国医学科学院中央级公益性科研院所基本科研业务费专项资金 2019XK320024

详细信息
    通讯作者:

    刘洁, E-mail: liujie04672@pumch.cn

  • 中图分类号: R739.5

Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors

Funds: 

National Natural Science Foundation of China 82173449

The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2019XK320024

More Information
  • 摘要: 死亡受体途径和穿孔素/颗粒酶途径是免疫系统杀伤肿瘤细胞的主要机制,SerpinB9是已知的人体中唯一能够抑制颗粒酶B(granzyme B,GrB)水解活性的蛋白。研究表明,肺癌、前列腺癌等肿瘤细胞可通过表达SerpinB9抵抗细胞毒性淋巴细胞通过穿孔素/GrB介导的杀伤作用。在皮肤肿瘤领域,恶性黑色素瘤、鳞状细胞癌及皮肤淋巴肿瘤细胞中均可检测到SerpinB9表达,并通过促进免疫逃逸、抵抗免疫治疗、影响肿瘤微环境等多种途径促进肿瘤进展。此外,已有研究证实SerpinB9抑制剂可抑制恶性黑色素瘤生长,表明SerpinB9可作为潜在的抗肿瘤治疗靶点。本文将对SerpinB9在皮肤肿瘤领域的研究现状进行综述。
    作者贡献:张姗和刘兆睿负责查阅文献、撰写及修订论文;刘洁负责设计选题和审校论文。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Irving JA, Pike RN, Lesk AM, et al. Phylogeny of the Serpin Superfamily: Implications of Patterns of Amino Acid Conservation for Structure and Function[J]. Genome Res, 2000, 10: 1845-1864. doi:  10.1101/gr.147800
    [2] Kaiserman D, Bird PI. Control of Granzymes by Serpins[J]. Cell Death Differ, 2010, 17: 586-595. doi:  10.1038/cdd.2009.169
    [3] Silverman GA, Whisstock JC, Askew DJ, et al. Human Clade B Serpins (Ov-serpins) Belong to a Cohort of Evolutionarily Dispersed Intracellular Proteinase Inhibitor Clades That Protect Cells From Promiscuous Proteolysis[J]. Cell Mol Life Sci, 2004, 61: 301-325. doi:  10.1007/s00018-003-3240-3
    [4] Wang WJ, Wang J, Ouyang C, et al. Overview of serpin B9 and its roles in cancer (Review)[J]. Oncol Rep, 2021, 46: 190. doi:  10.3892/or.2021.8141
    [5] Medema JP, de Jong J, Peltenburg LT, et al. Blockade of the Granzyme B/Perforin Pathway Through Overexpression of the Serine Protease Inhibitor PI-9/SPI-6 Constitutes a Mechanism for Immune Escape by Tumors[J]. Proc Natl Acad Sci U S A, 2001, 98: 11515-11520. doi:  10.1073/pnas.201398198
    [6] Sun JR, Bird CH, Sutton V, et al. A Cytosolic Granzyme B Inhibitor Related to the Viral Apoptotic Regulator Cytokine Response Modifier A Is Present in Cytotoxic Lymphocytes[J]. J Biol Chem, 1996, 271: 27802-27809. doi:  10.1074/jbc.271.44.27802
    [7] Zhang ML, Park SM, Wang Y, et al. Serine Protease Inhibitor 6 Protects Cytotoxic T Cells From Self-inflicted Injury by Ensuring the Integrity of Cytotoxic Granules[J]. Immunity, 2006, 24: 451-461. doi:  10.1016/j.immuni.2006.02.002
    [8] Ansari AW, Temblay JN, Alyahya SH, et al. Serine Protease Inhibitor 6 Protects iNKT Cells From Self-inflicted Damage[J]. J Immunol, 2010, 185: 877-883. doi:  10.4049/jimmunol.1000651
    [9] Bird CH, Sutton VR, Sun J, et al. Selective Regulation of Apoptosis: the Cytotoxic Lymphocyte Serpin Proteinase Inhibitor 9 Protects Against Granzyme B-mediated Apoptosis Without Perturbing the Fas Cell Death Pathway[J]. Mol Cell Biol, 1998, 18: 6387-6398. doi:  10.1128/MCB.18.11.6387
    [10] Kummer JA, Micheau O, Schneider P, et al. Ectopic Expression of the Serine Protease Inhibitor PI9 Modulates Death Receptor-mediated Apoptosis[J]. Cell Death Differ, 2007, 14: 1486-1496. doi:  10.1038/sj.cdd.4402152
    [11] Cunningham TD, Jiang XG, Shapiro DJ. Expression of High Levels of Human Proteinase Inhibitor 9 Blocks Both Perforin/Granzyme and Fas/Fas Ligand-mediated Cytotoxi-city[J]. Cell Immunol, 2007, 245: 32-41. doi:  10.1016/j.cellimm.2007.03.004
    [12] Bladergroen BA, Strik MC, Bovenschen N, et al. The Granzyme B Inhibitor, Protease Inhibitor 9, Is Mainly Expressed by Dendritic Cells and at Immune-privileged Sites[J]. J Immunol, 2001, 166: 3218-3225. doi:  10.4049/jimmunol.166.5.3218
    [13] Azzi J, Skartsis N, Mounayar M, et al. Serine Protease Inhibitor 6 Plays a Critical Role in Protecting Murine Granzyme B-producing Regulatory T Cells[J]. J Immunol, 2013, 191: 2319-2327. doi:  10.4049/jimmunol.1300851
    [14] Bladergroen BA, Strik MCM, Wolbink AM, et al. The Granzyme B Inhibitor Proteinase Inhibitor 9 (PI9) Is Expressed by Human Mast Cells[J]. Eur J Immunol, 2005, 35: 1175-1183. doi:  10.1002/eji.200425949
    [15] Buzza MS, Hirst CE, Bird CH, et al. The Granzyme B Inhibitor, PI-9, Is Present in Endothelial and Mesothelial Cells, Suggesting That It Protects Bystander Cells During Immune Responses[J]. Cell Immunol, 2001, 210: 21-29. doi:  10.1006/cimm.2001.1806
    [16] Rizzitelli A, Meuter S, Vega Ramos J, et al. Serpinb9 (Spi6)-deficient Mice Are Impaired in Dendritic Cell-mediated Antigen Cross-presentation[J]. Immunol Cell Biol, 2012, 90: 841-851. doi:  10.1038/icb.2012.29
    [17] Garrido F. MHC/HLA Class I Loss in Cancer Cells[J]. Adv Exp Med Biol, 2019, 1151: 15-78.
    [18] Rousalova I, Krepela E, Prochazka J, et al. Expression of Proteinase Inhibitor-9/serpinB9 in Non-small Cell Lung Carcinoma Cells and Tissues[J]. Int J Oncol, 2010, 36: 275-283.
    [19] Soriano C, Mukaro V, Hodge G, et al. Increased Proteinase Inhibitor-9 (PI-9) and Reduced Granzyme B in Lung Cancer: Mechanism for Immune Evasion?[J]. Lung Cancer, 2012, 77: 38-45. doi:  10.1016/j.lungcan.2012.01.017
    [20] Zhou B, Chen EL, Chen JH, et al. Overexpression of Proteinase Inhibitor 9 Is Associated With Poor Prognosis in Human Hepatocellular Carcinoma and With Proliferation and Apoptosis in HepG2 Cells in vitro[J]. Int J Clin Exp Pathol, 2019, 12: 3719-3727.
    [21] Vycital O, Pitule P, Hosek P, et al. Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer[J]. Anticancer Res, 2019, 39: 6063-6066. doi:  10.21873/anticanres.13813
    [22] Ray M, Hostetter DR, Loeb CRK, et al. Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis[J]. Prostate, 2012, 72: 846-855. doi:  10.1002/pros.21486
    [23] Fritsch K, Finke J, Grüllich C. Suppression of Granzyme B Activity and Caspase-3 Activation in Leukaemia Cells Constitutively Expressing the Protease Inhibitor 9[J]. Ann Hematol, 2013, 92: 1603-1609. doi:  10.1007/s00277-013-1846-6
    [24] Chen Y, Quan LN, Jia CM, et al. Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma[J]. J Proteome Res, 2021, 20: 2673-2686. doi:  10.1021/acs.jproteome.1c00007
    [25] van Houdt IS, Oudejans JJ, van den Eertwegh AJM, et al. Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients With Stage Ⅲ and Ⅳ Melanoma[J]. Clin Cancer Res, 2005, 11: 6400-6407. doi:  10.1158/1078-0432.CCR-05-0306
    [26] Van Allen EM, Miao DN, Schilling B, et al. Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma[J]. Science, 2015, 350: 207-211. doi:  10.1126/science.aad0095
    [27] Jiang P, Gu SQ, Pan D, et al. Signatures of T cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response[J]. Nat Med, 2018, 24: 1550-1558. doi:  10.1038/s41591-018-0136-1
    [28] Jiang XJ, Wang J, Deng XY, et al. Role of the Tumor Microenvironment in PD-L1/PD-1-mediated Tumor Immune Escape[J]. Mol Cancer, 2019, 18: 10. doi:  10.1186/s12943-018-0928-4
    [29] Jiang LW, Wang YJ, Zhao J, et al. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy[J]. Cell, 2020, 183: 1219-1233. e18. doi:  10.1016/j.cell.2020.10.045
    [30] Liu Y, Cao XT. Immunosuppressive Cells in Tumor Immune Escape and Metastasis[J]. J Mol Med (Berl), 2016, 94: 509-522. doi:  10.1007/s00109-015-1376-x
    [31] Luo H, Ma C. Identification of Prognostic Genes in Uveal Melanoma Microenvironment[J]. PLoS One, 2020, 15: e0242263. doi:  10.1371/journal.pone.0242263
    [32] Peters FS, Peeters AMA, van den Bosch TPP, et al. Disrupted Regulation of serpinB9 in Circulating T Cells Is Associated With an Increased Risk for Post-transplant Skin Cancer[J]. Clin Exp Immunol, 2019, 197: 341-351. doi:  10.1111/cei.13309
    [33] Bladergroen BA, Meijer CJLM, ten Berge RL, et al. Expression of the Granzyme B Inhibitor, Protease Inhibitor 9, by Tumor Cells in Patients With non-Hodgkin and Hodgkin Lymphoma: a Novel Protective Mechanism for Tumor Cells to Circumvent the Immune System?[J]. Blood, 2002, 99: 232-237. doi:  10.1182/blood.V99.1.232
    [34] ten Berge RL, Meijer CJLM, Dukers DF, et al. Expression Levels of Apoptosis-related Proteins Predict Clinical Outcome in Anaplastic Large Cell Lymphoma[J]. Blood, 2002, 99: 4540-4546. doi:  10.1182/blood.V99.12.4540
    [35] Bossard C, Belhadj K, Reyes F, et al. Expression of the Granzyme B Inhibitor PI9 Predicts Outcome in Nasal NK/T-cell Lymphoma: Results of a Western Series of 48 Patients Treated With First-line Polychemotherapy Within the Grouped'Etude des Lymphomes de l'Adulte (GELA) Trials[J]. Blood, 2007, 109: 2183-2189. doi:  10.1182/blood-2006-07-033142
  • 加载中
计量
  • 文章访问数:  10
  • HTML全文浏览量:  1
  • PDF下载量:  10
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-28
  • 录用日期:  2022-02-24
  • 网络出版日期:  2022-08-15
  • 刊出日期:  2022-09-30

目录

    /

    返回文章
    返回

    【通知】尊敬的读者、作者及编者:因特殊原因,本站自2022.9.30至10.24日期间实施6—24点开放,其他时段访问受限,给您带来不便敬请谅解!10.25日恢复如常。